Phenylpyrimidone Compounds PDE5 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE5 inhibitors, such as sildenafil, exhibit side effects like headache and vision disorders due to non-selective inhibition of phosphodiesterase isoenzymes, necessitating the development of compounds with stronger activity and increased selectivity for PDE5 over PDE6 to reduce these adverse effects.
Innovation Solution
Development of novel phenylpyrimidone compounds with specific structural features that enhance PDE5 inhibition while minimizing interaction with PDE6, thereby reducing side effects and improving clinical safety and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sildenafil is used to inhibit PDE5, then erectile dysfunction treatment effect is improved, but side effects such as headache and vision disorders occur due to non-selective inhibition of phosphodiesterase isoenzymes
Solution Approach 1:
The patent applies local quality by designing a chemical structure with specific functional groups at specific positions: a pyrimidone core with particular substituents including a heterocyclic group at position 2, an electron-withdrawing group at position 5, and specific R1-R6 definitions that create localized electronic and steric properties. This localized structural optimization enables selective binding to PDE5 while minimizing interaction with other phosphodiesterase isoenzymes, thereby maintaining treatment efficacy while reducing side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types (heterocyclic groups, electron-withdrawing groups), their positions on the pyrimidone core, and molecular configuration. These parameter optimizations adjust the compound's binding affinity and selectivity profile, enabling stronger PDE5 inhibition with reduced off-target effects compared to sildenafil.
2Reliability
If the inhibition activity of PDE5 is increased to reduce side effects, then selectivity for PDE5 over PDE6 should be improved, but developing such selective compounds requires novel chemical structures and synthesis approaches
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a pyrimidone core structure, heterocyclic substituents at specific positions, and electron-withdrawing groups. This segmented approach allows systematic optimization of each segment's contribution to PDE5 selectivity while managing overall molecular complexity through modular design.
Solution Approach 2:
The patent employs composite material principles by combining multiple chemical moieties with complementary functions into a single molecular entity. The composite structure integrates the pyrimidone core with heterocyclic groups and electron-withdrawing substituents, creating a molecule with optimized electronic distribution and steric properties that enhance PDE5 selectivity while maintaining manageable synthesis complexity.
Data Source
AI summary
The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof; and to the pharmaceutical composition as well as the preparation method of the said compounds. The said compounds of formula I according to the present invention can effectively inhibit type V phosphodiesterase (PDE5), and thus can be used for the treatment of various vascular disorders, such as male erectile dysfunction, pulmonary hypertension and the like.